Parexel launches integrated FPS model to drive delivery of clinical research partnerships

24th June 2019 (Last Updated June 25th, 2019 09:43)

Parexel, a company with a focus on developing new therapies to improve patient health, has unveiled an enhanced integrated outsourcing delivery model for functional service provider (FSP) services, at the DIA 2019 Global Annual Meeting held in San Diego, US.

Parexel launches integrated FPS model to drive delivery of clinical research partnerships
Parexel’s enhanced integrated Functional Service Provider model is intended to drive the delivery of innovative clinical research partnerships. Credit: PublicDomainPictures from Pixabay

Parexel, a company with a focus on developing new therapies to improve patient health, has unveiled an enhanced integrated outsourcing delivery model for functional service provider (FSP) services, at the DIA 2019 Global Annual Meeting held in San Diego, US.

According to the company, the FSP model reflects the strategic focus that it has towards offering solutions that are patient-focused and are tailored as per the biopharma customers’ changing needs, ranging from full service to a functional and a hybrid approach across a range of specialised disciplines including clinical, data management, safety, regulatory and medical affairs.

Parexel executive vice president and chief commercial and strategy officer Peyton Howell said: “With functional services and related blended models representing a significant proportion of total clinical development spend today, biopharma companies need flexible and hybrid approaches to their outsourcing needs.

“Parexel is an FSP ideal partner, with a proven track record in connecting and delivering targeted needs with increased expertise across functional services and an ability to integrate seamlessly with our customers’ teams.”

Parexel develops a wide range of FSP, full and flexible clinical development services. So far, it has delivered over 1,400 projects.

Leveraging the expertise offered by its TMAC and ExecuPharm subsidiaries, Parexel provides a comprehensive FSP with hybrid capability.

Howell added: “For example, our ExecuPharm subsidiary provides biopharma customers with qualified professionals across functional areas, including clinical monitoring and study management. TMAC provides strategic and tactical solutions, including contract field based medical teams, medical science liaisons, medical information and medical affairs consulting.”

Recently, Parexel entered into a strategic partnership with Clariness, a global patient recruitment company, to speed up clinical trial recruitment and patient engagement in China.

Parexel has eight offices and over 1,400 employees in China, where it has been operating for the last two decades.

It also has over 8,000 employees in the Asia-Pacific region.